Ken Griffin Neogenomics Inc Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Neogenomics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 253,600 shares of NEO stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
253,600
Previous 135,000
87.85%
Holding current value
$2.52 Million
Previous $1.99 Million
109.89%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding NEO
# of Institutions
282Shares Held
124MCall Options Held
751KPut Options Held
107K-
Black Rock Inc. New York, NY19.7MShares$196 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$142 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.53MShares$65 Million0.07% of portfolio
-
Janus Henderson Group PLC London, X06.17MShares$61.3 Million0.05% of portfolio
-
Brown Advisory Inc6.16MShares$61.3 Million0.13% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.25B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...